Cell-free RNA signatures predict Alzheimer’s disease
Alejandro Cisterna‐García, Aleksandra Beric, Muhammad Ali, Jose Adrian Pardo, Hsiang‐Han Chen, María Victoria Fernández, Joanne Norton, Jen Gentsch, Kristy Bergmann, John Budde, Joel S. Perlmutter, John C. Morris, Carlos Cruchaga, Juan A. Botía, Laura Ibáñez
Abstract
There is a need for affordable, scalable, and specific blood-based biomarkers for Alzheimer's disease that can be applied to a population level. We have developed and validated disease-specific cell-free transcriptomic blood-based biomarkers composed by a scalable number of transcripts that capture AD pathobiology even in the presymptomatic stages of the disease. Accuracies are in the range of the current CSF and plasma biomarkers, and specificities are high against other neurodegenerative diseases.